Forth Raises ￡1.6m To Invest In FemTech

Forth is set to capitalise on the growth in the female science and technology market as it has secured ￡1.6m funding to support the launch of its ground-breaking female health product.

Leading the team at Forth is CEO and Co-Founder Sarah Bolt. She said: “Today, more and more people are realising that understanding and measuring your body’s biochemistry is key for a long and healthy life. For women, in particular, gaining a unique insight into how their hormone levels fluctuate throughout their unique cycle can give women the support they have been lacking and help to close the gender health gap”.??????

Forth’s investment round has attracted backing from a consortium of both UK and overseas investors including, Trajan Scientific and Medical, (Trajan) through its European subsidiary Trajan Scientific Europe Ltd. Headquartered in Melbourne, Australia, Trajan is a global developer and manufacturer of analytical science instruments, devices and solutions and has major operations in Australia, Europe, US and Asia.?

Stephen Tomisich, Chief Executive Officer and Managing Director, Trajan stated, “We have known the founders and majority shareholders at Forth for some time. We share common values around delivering good science that helps people achieve better health outcomes. We are both intensely focussed on delivering impact and working together we believe we will do just that.”

The Development Bank of Wales has also supported this second round of funding with follow-on equity of ￡250,000 bringing its total investment to date to ￡500,000. Senior Investment Executive Alexander Leigh said: “?Sarah and the team have done incredibly well to secure a strong market position in a rapidly growing sector. The company is ranked by Trustpilot as the highest rated service in the sector and has all the drive and the skills to deliver on their vision.

“Our follow-on equity funding coupled with Trajan’s strategic investment will now give Forth unique access to cutting edge technologies as they develop their innovative product offering with Female Hormone Mapping. We‘re proud to be behind this great team and wish them every success.”

Forth reported revenue growth of over 100% in June 2020 compared to the previous year. The company was then awarded an innovation grant in September 2020 to develop a unique female hormone product.?In 2020 founder and CEO, Sarah Bolt won Health & Wellbeing Entrepreneur of the Year for Wales at the Great British Entrepreneur Awards and is currently a finalist for the Natwest everywoman Award.

Sarah Bolt added: “Our mission at Forth is simple - to give people a better understanding of their own body using a combination of science and technology. This investment will enable us to launch Female Hormone Mapping and also develop more unique and insightful products to help people engage proactively with their health.?Trajan is a perfect partner as we share a focus on using science to advance preventative health while the Development Bank continues to support us as a Welsh-based company that is at the forefront of the femtech market. “

About Forth

Launched in 2016, Forth is one of the UK’s leading companies in personalised biomarker tracking. Starting with a small sample of blood, the company helps people to navigate their way to better health by providing clear scientific data about their body’s biochemistry, together with expert advice to help them improve. Since starting raising initial seed investment the company has gone from strength to strength and recently launched a ground-breaking product to help women gain better insight into their hormone fluctuations. Female Hormone Mapping is the first product in the world to use AI to help map how a woman’s hormones fluctuate throughout their entire cycle, rather than a single day which is current clinical practice. The product is particularly useful for those who want the certainty of entering perimenopause, a time of life, where women are lacking sufficient support.

About Trajan

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to have a positive impact on human wellbeing through scientific measurement. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of 450 people, with five manufacturing sites across the US, Australia, and Malaysia, and operations in Australia, the US, Asia, and Europe.